Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials
Open Access
- 28 April 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (8) , 2368-2377
Abstract
Objectives: To evaluate the efficacy of anidulafungin for the treatment of candidaemia and invasive candidiasis in a large dataset, including patients with deep-seated tissue candidiasis, neutropenia and infection due to non-albicans Candida species. Methods: Data were pooled from six prospective, multicentre, multinational studies: four open-label, non-comparative studies of anidulafungin and two double-blind, double-dummy, randomized studies of anidulafungin versus caspofungin (clinical trial registrations: NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; ClinicalTrials.gov). In all studies, patients with culture-confirmed invasive candidiasis received a single intravenous (iv) loading dose of anidulafungin 200 mg on day 1, followed by 100 mg once-daily. Switch to oral fluconazole or voriconazole was permitted after 5–10 days of iv treatment in all studies except one. Antifungal treatment (iv plus oral therapy if applicable) was maintained for ≥14 days after the last positive Candida culture. The primary endpoint was successful global response at end of iv therapy (EOivT) in the modified ITT (mITT) population. Results: In total, 539 patients were included (mITT population). The most common baseline Candida species were Candida albicans (47.9%), Candida glabrata (21.0%), Candida tropicalis (13.7%), Candida parapsilosis (13.2%) and Candida krusei (3.5%). Median duration of anidulafungin iv treatment was 10.0 days. The global response success rate at EOivT was 76.4% (95% CI 72.9%–80.0%). All-cause mortality was 13.0% on day 14 and 19.1% on day 28. Adverse events (AEs) were consistent with the known AE profile for anidulafungin. Conclusions: These data demonstrate that anidulafungin is effective for treatment of candidaemia and invasive candidiasis in a broad patient population.Keywords
This publication has 34 references indexed in Scilit:
- Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trialBMC Infectious Diseases, 2013
- Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patientsClinical Microbiology and Infection, 2012
- Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance MutationsAntimicrobial Agents and Chemotherapy, 2012
- Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic HostsAntimicrobial Agents and Chemotherapy, 2011
- In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida SpeciesAntimicrobial Agents and Chemotherapy, 2010
- Caspofungin Use in Patients with Invasive Candidiasis Caused by Common Non- albicans Candida Species: Review of the Caspofungin DatabaseAntimicrobial Agents and Chemotherapy, 2010
- In Vitro Fungicidal Activities of Echinocandins against Candida metapsilosis , C. orthopsilosis , and C. parapsilosis Evaluated by Time-Kill StudiesAntimicrobial Agents and Chemotherapy, 2010
- Candida krusei , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005Journal of Clinical Microbiology, 2008
- In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global SurveillanceJournal of Clinical Microbiology, 2008
- Effects of Caspofungin against Candida guilliermondii and Candida parapsilosisAntimicrobial Agents and Chemotherapy, 2006